NCT04434781 Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastroparesis
| NCT ID | NCT04434781 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Indiana University |
| Condition | Gastroparesis |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2018-08-07 |
| Primary Completion | 2026-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2018-08-07 with a primary completion date of 2026-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gastric Per-Oral Endoscopic Myotomy (G-POEM) is a procedure for the Treatment of Gastroparesis.
Eligibility Criteria
Inclusion Criteria: * 18 years of age * Referral for endoscopic treatment of Gastroparesis for symptom management Exclusion Criteria: * \< 18 years of age * Absence of gastroparesis based on scintigraphy studies
Contact & Investigator
Mohammad Al-Haddad, MD
PRINCIPAL INVESTIGATOR
Indiana University
Frequently Asked Questions
Who can join the NCT04434781 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastroparesis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04434781 currently recruiting?
Yes, NCT04434781 is actively recruiting participants. Contact the research team at petermaj@iu.edu for enrollment information.
Where is the NCT04434781 trial being conducted?
This trial is being conducted at Indianapolis, United States.
Who is sponsoring the NCT04434781 clinical trial?
NCT04434781 is sponsored by Indiana University. The principal investigator is Mohammad Al-Haddad, MD at Indiana University. The trial plans to enroll 75 participants.